RxDoctor Payments Data

Stephanie Kunz

Nurse Practitioner · Mobile, ALNPI 1316552979

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 156 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$768
  • Abbott$459
  • Pfizer$330
  • Boehringer Ingelheim$265
  • E.r. Squibb & Sons, L.L.C.$197
  • Boston Scientific$166
  • plus $672 from 11 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$46,531
Medicare patients
452
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$206,616
XareltoRivaroxaban109$107,836
EntrestoSacubitril/Valsartan39$43,004
Dofetilide16$5,488
Bisoprolol Fumarate169$5,458
Ranolazine ErRanolazine52$4,079
Flecainide Acetate92$3,602
Potassium Chloride122$2,427
SotalolSotalol Hcl65$2,412
Midodrine Hcl38$2,200
Propafenone Hcl ErPropafenone Hcl11$2,111
Amiodarone Hcl136$2,053
Metoprolol Succinate111$1,764
Propafenone Hcl29$1,707
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$330$206,616241 claims
Johnson & JohnsonXarelto$768$107,836109 claims
NovartisEntresto$119$43,00439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →